- Home
- EFSI vs GALT Comparison
EFSI vs GALT Comparison
Compare EFSI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSI
- GALT
- Stock Information
- Founded
- EFSI 1881
- GALT 2000
- Country
- EFSI United States
- GALT United States
- Employees
- EFSI N/A
- GALT N/A
- Industry
- EFSI Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- EFSI Finance
- GALT Health Care
- Exchange
- EFSI Nasdaq
- GALT Nasdaq
- Market Cap
- EFSI 201.2M
- GALT 232.3M
- IPO Year
- EFSI N/A
- GALT N/A
- Fundamental
- Price
- EFSI $37.30
- GALT $4.54
- Analyst Decision
- EFSI Strong Buy
- GALT Strong Buy
- Analyst Count
- EFSI 2
- GALT 3
- Target Price
- EFSI $39.50
- GALT $6.00
- AVG Volume (30 Days)
- EFSI 8.9K
- GALT 348.2K
- Earning Date
- EFSI 07-24-2025
- GALT 11-12-2025
- Dividend Yield
- EFSI 3.37%
- GALT N/A
- EPS Growth
- EFSI N/A
- GALT N/A
- EPS
- EFSI 1.85
- GALT N/A
- Revenue
- EFSI $61,734,000.00
- GALT N/A
- Revenue This Year
- EFSI N/A
- GALT N/A
- Revenue Next Year
- EFSI $28.84
- GALT N/A
- P/E Ratio
- EFSI $19.82
- GALT N/A
- Revenue Growth
- EFSI N/A
- GALT N/A
- 52 Week Low
- EFSI $28.70
- GALT $0.73
- 52 Week High
- EFSI $37.50
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- EFSI 67.28
- GALT 52.90
- Support Level
- EFSI $36.56
- GALT $4.35
- Resistance Level
- EFSI $37.34
- GALT $6.55
- Average True Range (ATR)
- EFSI 0.47
- GALT 0.44
- MACD
- EFSI -0.11
- GALT -0.07
- Stochastic Oscillator
- EFSI 74.14
- GALT 17.11
About EFSI Eagle Financial Services Inc Common Stock
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.